黎巴嫩患者中产超广谱β-内酰胺酶菌株的表型和分子特征分析以及……（原文“and among Lebanese patients”表述不完整，这里按已有内容尽量准确翻译）

Phenotypic and molecular characterization of ESBL producing and among Lebanese patients.

作者信息

El-Hariri Saria A, Saleh Fatima, Moghnieh Wafaa, Sokhn Elie S

机构信息

Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon.

出版信息

JAC Antimicrob Resist. 2023 Jun 9;5(3):dlad074. doi: 10.1093/jacamr/dlad074. eCollection 2023 Jun.

DOI:10.1093/jacamr/dlad074

PMID:37305848

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10251202/

Abstract

INTRODUCTION

Antimicrobial resistance is a major public health issue worldwide and became one of the principal international healthcare crises of the 21st century. The production of ESBLs is one of the resistance mechanisms in Enterobacteriaceae, and they are increasingly detected in and globally. Therefore, the aim of this study was to determine the phenotypic and molecular characteristics of ESBL-producing and among Lebanese patients.

METHODS

A total of 152 ESBL-producing and were obtained from Geitaoui Hospital in Beirut between September 2019 and October 2020 from various clinical samples. The phenotype of ESBL producers was confirmed by a double-disc synergy test and antibiotic susceptibility was determined using the disc diffusion method. Genotypically, multiplex PCR was used to detect the ESBL genes (, and ).

RESULTS

All strains were confirmed to be ESBL producers (121 isolates were and 31 isolates were ). All isolates showed resistance to cefotaxime, cefuroxime, ampicillin and piperacillin. On the other hand, they showed a low susceptibility rate to trimethoprim/sulfamethoxazole and ciprofloxacin. Almost all the isolates were susceptible to ertapenem, imipenem and amikacin. In our study, ESBL genes were detected among 48 (39.67%) isolates and 8 (58.06%) isolates, and the most prevalent gene was (25%), followed by (19.08%) and (16.45%).

CONCLUSION

Imipenem and ertapenem are the most effective drugs to treat ESBL producers. However, antibiotic stewardship programs must be implemented immediately to combat antibiotic resistance.

摘要

引言

抗菌药物耐药性是全球主要的公共卫生问题，已成为21世纪主要的国际医疗危机之一。超广谱β-内酰胺酶（ESBLs）的产生是肠杆菌科细菌的耐药机制之一，并且在全球范围内其检出率日益增加。因此，本研究的目的是确定黎巴嫩患者中产ESBL的大肠埃希菌和肺炎克雷伯菌的表型及分子特征。

方法

2019年9月至2020年10月期间，从贝鲁特的盖陶伊医院的各种临床样本中总共获得了152株产ESBL的大肠埃希菌和肺炎克雷伯菌。通过双纸片协同试验确认ESBL产生菌的表型，并使用纸片扩散法测定抗生素敏感性。在基因层面，采用多重PCR检测ESBL基因（blaCTX-M、blaTEM和blaSHV）。

结果

所有菌株均被确认为ESBL产生菌（121株分离菌为大肠埃希菌，31株分离菌为肺炎克雷伯菌）。所有分离株均对头孢噻肟、头孢呋辛、氨苄西林和哌拉西林耐药。另一方面，它们对甲氧苄啶/磺胺甲恶唑和环丙沙星的敏感率较低。几乎所有分离株对厄他培南、亚胺培南和阿米卡星敏感。在我们的研究中，在48株（39.67%）大肠埃希菌分离株和8株（58.06%）肺炎克雷伯菌分离株中检测到ESBL基因，最常见的基因是blaCTX-M（25%），其次是blaTEM（19.08%）和blaSHV（16.45%）。